Breakout Bulletin: April 19-24

You’re busy. Between patients, prior authorizations, and everything else on your plate, keeping up with the literature is the first thing that slips. NP/PA Connect is here to make sure it doesn’t. Each week, we pull the most clinically relevant news from across dermatology and bring it straight to your inbox — what’s new, what it means, and what’s worth watching. This week: a biologic approval that fills a long-standing gap in pediatric CSU, new long-term data that makes the case for treating atopic dermatitis more aggressively, a first-in-class mechanism for alopecia areata that could challenge JAK inhibitors, and what 2 new aesthetic studies say about patients you’re already seeing more of.

Dupilumab Is Now Approved for CSU in Kids as Young as 2

The FDA has approved dupilumab for chronic spontaneous urticaria in children aged 2 to 11 who remain symptomatic despite H1 antihistamine therapy — making it the first biologic approved in the US for this age group. The decision extends an existing approval that already covered adults and adolescents 12 and older, and addresses a gap that has left clinicians cycling through symptom-focused options with limited effect for an estimated 14,000 children in this age range.¹

The mechanistic distinction matters here. Standard antihistamines manage symptoms without touching the underlying inflammatory drivers. Dupilumab works upstream, blocking IL-4 and IL-13 signaling — the same type 2 pathway driving atopic dermatitis and asthma. The pediatric approval is grounded in the LIBERTY-CUPID (NCT04180488) phase 3 program, with efficacy in the 2 to 11 age group extrapolated from robust adult and adolescent data in Studies A and C, supported by pharmacokinetic and safety data from the single-arm CUPIDKids trial. Dosing is weight-based. The safety profile was consistent with dupilumab’s established record across its other indications, with injection site reactions the most common adverse event and no new signals in the youngest cohort.

This is dupilumab’s 9th approved US indication and its 5th extended to children under 12. For APPs managing pediatric patients who’ve exhausted antihistamine options, there is now a biologic with a well-characterized safety profile and a mechanism that actually addresses the disease.

▶ Why it matters: Antihistamine-refractory CSU in young children has had no good answers. This approval changes that conversation with parents entirely.

MORE ON PEDIATRICS

In Atopic Dermatitis, Aiming Higher Gets Your Patients More

Two post hoc analyses from the Measure Up 1 (NCT03569293) and 2 (NCT03607422) phase 3 trials, both presented at AAD 2026, reinforce what the AHEAD treat-to-target framework has been arguing for years: in atopic dermatitis, near-complete clearance isn’t just a clinical milestone — it’s the threshold at which patients’ lives actually change.

The first analysis stratified patients by response depth at week 16. Those who achieved the optimal target — EASI-90 plus minimal itch (WP-NRS 0 or 1) — reported dramatically better outcomes across every domain that matters to patients: quality of life, sleep, pain, anxiety, depression, and daily functioning. Treatment satisfaction hit 82% in the optimal group versus 68.6% in those who reached only a moderate response. The gradient was consistent and clear: more clearance, more benefit, across the board.²

The second analysis asked whether those gains hold. Among patients who hit stringent PRO thresholds at week 16 on upadacitinib 15 mg or 30 mg and stayed on therapy, 60% to 80% maintained those responses through week 140 — nearly 3 years of follow-up. Itch control, sleep quality, emotional well-being, and treatment satisfaction all remained stable over time.³

Taken together, these analyses make a practical case for not settling. If a patient is moderately improved but still scratching at night or avoiding social situations, that’s not the ceiling — it’s a signal to reassess the treatment plan.

▶ Why it matters: The data gives providers a clinical argument for escalating therapy when patients plateau at “good enough” — because optimal control is both achievable and durable.

MORE FROM AAD

A New Mechanism Is Coming for Alopecia Areata — And It’s Not a JAK Inhibitor

Rezpegaldesleukin (REZPEG), a first-in-class IL-2 pathway agonist, continued to impress in 52-week data from the REZOLVE-AA (NCT06340360) phase 2b extension, offering an early look at what a Treg-based approach to alopecia areata could look like in practice.⁴ The mechanism is fundamentally different from JAK inhibitors: rather than broadly suppressing immune signaling, rezpegaldesleukin selectively expands and activates regulatory T cells to restore immune tolerance at the source of follicular attack.

In the extension cohort — patients who had not yet hit a SALT ≥20 response by week 36 and continued therapy through week 52 — 29% to 31% achieved new responses during that additional 16-week window. Across the full study population at 52 weeks, SALT ≥20 rates reached 25.8% and 27.6% in the low- and high-dose groups, respectively, versus 6.7% with placebo. Ninety-four percent of patients completed the full year on therapy, and no new safety signals emerged.

“Given the prescribing and safety limitations of JAK inhibitors, these new data point to the potential forrezpegaldesleukin to be the first safe and effective biologic in alopecia areata, which may completely transform the management of the disease.” — Jonathan Silverberg, MD, PhD, MPH, The George Washington University

The drug already holds FDA Fast Track designation for both alopecia areata and atopic dermatitis. Response rates continue to build with time — a pattern that mirrors what the same mechanism showed in earlier atopic dermatitis work. For patients who are not candidates for JAK inhibitors, or who are hesitant about the associated safety conversations, a biologic option with a distinct mechanism would meaningfully expand the toolkit.

▶ Why it matters: JAK inhibitors transformed AA management, but they come with real prescribing constraints. A safe, effective biologic alternative would change the calculus for a large subset of patients.

MORE ON ALOPECIA

Two Patient Populations You’re Already Seeing More Of — and What the Science Now Says

Two investigator-initiated studies from Galderma, presented at a recent scientific meeting, add biological grounding to clinical patterns APPs in aesthetic practice are already observing.⁵

The first, led by Andreas Nikolis, MD, PhD, followed menopausal women through a 9-month treatment sequencing trial using Restylane Skinboosters and Sculptra on the face and décolletage. Both sequences produced progressive improvements in hydration, elasticity, and barrier function, with the most pronounced early hydration gains when Skinboosters were administered first. The mechanistic rationale holds up: hyaluronic acid improves extracellular matrix hydration rapidly, while poly-L-lactic acid drives gradual collagen and elastin remodeling over time. Patient satisfaction climbed steadily, reaching high levels by month 6. Menopausal patients are a frequently undertreated aesthetic population despite well-documented shifts in skin physiology — these interim data give clinicians a sequencing framework worth considering.

The second study, led by Sabrina Fabi, MD, looked at patients experiencing aesthetic changes after medication-driven weight loss — the GLP-1 face and body conversation that is increasingly showing up in exam rooms. Among 20 female patients with abdominal skin laxity, investigators found a statistically significant 4-fold reduction in adipose-derived stem cells compared to patients without medication-driven weight loss, while fibroblast populations remained intact. The finding suggests the volume loss and laxity these patients report isn’t just about fat reduction — there’s a selective shift in adipose biology that may explain why changes feel disproportionate to the number on the scale.

“Many people experiencing medication-driven weight loss report aesthetic changes that seem disproportionate to weight loss alone, and until now, we haven’t fully understood why.” — Sabrina Fabi, MD, trial investigator

Note: The indications for Restylane Skinboosters and Sculptra referenced in these studies are not currently FDA approved in the US. Both datasets are interim and from small cohorts; larger controlled trials will be needed.

▶ Why it matters: Your GLP-1 patients are going to keep coming in with these concerns. Having a biological explanation for what’s happening — and a treatment rationale to match — makes for a more informed and more confident conversation.

MORE ON GLP-1s

Interested in contributing to Dermatology Times NP/PA Connect? Contact editor Maddi Hebebrand at [email protected] to learn more!

References

1. Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria. News release. Sanofi. Published April 22, 2026. Accessed April 23, 2026. https://www.news.sanofi.us/2026-04-22-Sanofi-and-Regenerons-Dupixent-approved-in-the-US-as-the-first-biologic-medicine-for-young-children-with-uncontrolled-chronic-spontaneous-urticaria
2. Kirchhof M, Bunick C, Savage L, et al. Impact of optimal vs moderate skin and itch treatment targets on patient-reported outcomes in moderate-to-severe atopic dermatitis: insights from measure up 1 and 2 phase 3 studies. Poster presented at: 2026 American Academy of Dermatology Annual Meeting; March 27-31, 2026; Denver, Colorado.
3. Bunick C, Chovatiya R, Torres T, et al. Long-term maintenance of stringent patient-reported outcomes with upadacitinib in moderate-to-severe atopic dermatitis: 140-week results from the measure up 1 and 2 phase 3 studies. Poster presented at: 2026 American Academy of Dermatology Annual Meeting; March 27-31, 2026; Denver, Colorado.
4. 52-Week topline results from 16-week blinded treatment extension of REZOLVE-AA demonstrate deepening of responses in severe-to-very-severe alopecia areata with rezpegaldesleukin. News release. Nektar Therapeutics. April 20, 2026. Accessed April 23, 2026. https://www.prnewswire.com/news-releases/52-week-topline-results-from-16-week-blinded-treatment-extension-of-rezolve-aa-demonstrate-deepening-of-responses-in-severe-to-very-severe-alopecia-areata-with-rezpegaldesleukin-302746837.html
5. Interim data from two ongoing investigator-initiated trials highlight the role of Sculptra® and Restylane® in addressing aesthetic changes associated with weight loss medications and menopause. News release. Galderma. Published April 9, 2026. Published April 23, 2026. https://www.galderma.com/news/interim-data-two-ongoing-investigator-initiated-trials-highlight-role-sculptra-and-restylane